Metastatic Breast Cancer - Pipeline Review, H1 2016


#746139

1079pages

Global Markets Direct

$ 2000

In Stock

Metastatic Breast Cancer - Pipeline Review, H1 2016

Summary

Global Markets Directs, Metastatic Breast Cancer - Pipeline Review, H1 2016, provides an overview of the Metastatic Breast Cancer pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Metastatic Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Breast Cancer and features dormant and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer
- The report reviews pipeline therapeutics for Metastatic Breast Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Metastatic Breast Cancer therapeutics and enlists all their major and minor projects
- The report assesses Metastatic Breast Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Metastatic Breast Cancer


Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2
Introduction 8
Metastatic Breast Cancer Overview 9
Therapeutics Development 10
Metastatic Breast Cancer - Therapeutics under Development by Companies 12
Metastatic Breast Cancer - Therapeutics under Investigation by Universities/Institutes 23
Metastatic Breast Cancer - Pipeline Products Glance 24
Metastatic Breast Cancer - Products under Development by Companies 28
Metastatic Breast Cancer - Products under Investigation by Universities/Institutes 43
Metastatic Breast Cancer - Companies Involved in Therapeutics Development 44
Metastatic Breast Cancer - Therapeutics Assessment 172
Drug Profiles 200
Metastatic Breast Cancer - Recent Pipeline Updates 689
Metastatic Breast Cancer - Dormant Projects 1024
Metastatic Breast Cancer - Discontinued Products 1038
Metastatic Breast Cancer - Product Development Milestones 1043
Appendix 1053

List of Tables
Number of Products under Development for Metastatic Breast Cancer, H1 2016 35
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H1 2016 36
Number of Products under Development by Companies, H1 2016 38
Number of Products under Development by Companies, H1 2016 (Contd..1) 39
Number of Products under Development by Companies, H1 2016 (Contd..2) 40
Number of Products under Development by Companies, H1 2016 (Contd..3) 41
Number of Products under Development by Companies, H1 2016 (Contd..4) 42
Number of Products under Development by Companies, H1 2016 (Contd..5) 43
Number of Products under Development by Companies, H1 2016 (Contd..6) 44
Number of Products under Development by Companies, H1 2016 (Contd..7) 45
Number of Products under Development by Companies, H1 2016 (Contd..8) 46
Number of Products under Development by Companies, H1 2016 (Contd..9) 47
Number of Products under Investigation by Universities/Institutes, H1 2016 48
Comparative Analysis by Late Stage Development, H1 2016 49
Comparative Analysis by Clinical Stage Development, H1 2016 50
Comparative Analysis by Early Stage Development, H1 2016 51
Comparative Analysis by Unknown Stage Development, H1 2016 52
Products under Development by Companies, H1 2016 53
Products under Development by Companies, H1 2016 (Contd..1) 54
Products under Development by Companies, H1 2016 (Contd..2) 55
Products under Development by Companies, H1 2016 (Contd..3) 56
Products under Development by Companies, H1 2016 (Contd..4) 57
Products under Development by Companies, H1 2016 (Contd..5) 58
Products under Development by Companies, H1 2016 (Contd..6) 59
Products under Development by Companies, H1 2016 (Contd..7) 60
Products under Development by Companies, H1 2016 (Contd..8) 61
Products under Development by Companies, H1 2016 (Contd..9) 62
Products under Development by Companies, H1 2016 (Contd..10) 63
Products under Development by Companies, H1 2016 (Contd..11) 64
Products under Development by Companies, H1 2016 (Contd..12) 65
Products under Development by Companies, H1 2016 (Contd..13) 66
Products under Development by Companies, H1 2016 (Contd..14) 67
Products under Investigation by Universities/Institutes, H1 2016 68
Metastatic Breast Cancer - Pipeline by AB Science SA, H1 2016 69
Metastatic Breast Cancer - Pipeline by AbbVie Inc., H1 2016 70
Metastatic Breast Cancer - Pipeline by Acceleron Pharma, Inc., H1 2016 71
Metastatic Breast Cancer - Pipeline by Acetylon Pharmaceuticals, Inc., H1 2016 72
Metastatic Breast Cancer - Pipeline by Adgero Biopharmaceuticals, Inc., H1 2016 73
Metastatic Breast Cancer - Pipeline by Advaxis, Inc., H1 2016 74
Metastatic Breast Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2016 75
Metastatic Breast Cancer - Pipeline by Alteogen Inc., H1 2016 76
Metastatic Breast Cancer - Pipeline by Amarna Therapeutics B.V., H1 2016 77
Metastatic Breast Cancer - Pipeline by Ambrx, Inc., H1 2016 78
Metastatic Breast Cancer - Pipeline by Amgen Inc., H1 2016 79
Metastatic Breast Cancer - Pipeline by Aphios Corporation, H1 2016 80
Metastatic Breast Cancer - Pipeline by arGEN-X BV, H1 2016 81
Metastatic Breast Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2016 82
Metastatic Breast Cancer - Pipeline by Astellas Pharma Inc., H1 2016 83
Metastatic Breast Cancer - Pipeline by AstraZeneca Plc, H1 2016 84
Metastatic Breast Cancer - Pipeline by Bayer AG, H1 2016 85
Metastatic Breast Cancer - Pipeline by Beta Pharma, Inc., H1 2016 86
Metastatic Breast Cancer - Pipeline by Biocon Limited, H1 2016 87
Metastatic Breast Cancer - Pipeline by Bionovis SA, H1 2016 88
Metastatic Breast Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2016 89
Metastatic Breast Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2016 90
Metastatic Breast Cancer - Pipeline by Campus Technologies Freiburg GmbH, H1 2016 91
Metastatic Breast Cancer - Pipeline by CASI Pharmaceuticals Inc., H1 2016 92
Metastatic Breast Cancer - Pipeline by Celgene Corporation, H1 2016 93
Metastatic Breast Cancer - Pipeline by Celldex Therapeutics, Inc., H1 2016 94
Metastatic Breast Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2016 95
Metastatic Breast Cancer - Pipeline by Celltrion, Inc., H1 2016 96
Metastatic Breast Cancer - Pipeline by Clovis Oncology, Inc., H1 2016 97
Metastatic Breast Cancer - Pipeline by Corcept Therapeutics Incorporated, H1 2016 98
Metastatic Breast Cancer - Pipeline by Curadis GmbH, H1 2016 99
Metastatic Breast Cancer - Pipeline by Curaxys, S.L., H1 2016 100
Metastatic Breast Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2016 101
Metastatic Breast Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2016 102
Metastatic Breast Cancer - Pipeline by DexTech Medical AB, H1 2016 103
Metastatic Breast Cancer - Pipeline by Dompe Farmaceutici S.p.A., H1 2016 104
Metastatic Breast Cancer - Pipeline by Dr. Reddy's Laboratories Limited, H1 2016 105
Metastatic Breast Cancer - Pipeline by EirGenix Inc., H1 2016 106
Metastatic Breast Cancer - Pipeline by Eisai Co., Ltd., H1 2016 107
Metastatic Breast Cancer - Pipeline by Eli Lilly and Company, H1 2016 108
Metastatic Breast Cancer - Pipeline by Ensol Biosciences Inc., H1 2016 109
Metastatic Breast Cancer - Pipeline by EOS Biosciences, Inc., H1 2016 110
Metastatic Breast Cancer - Pipeline by Epigen Biosciences, Inc., H1 2016 111
Metastatic Breast Cancer - Pipeline by Etubics Corporation, H1 2016 112
Metastatic Breast Cancer - Pipeline by Eureka Therapeutics, Inc., H1 2016 113
Metastatic Breast Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 114
Metastatic Breast Cancer - Pipeline by Gene Techno Science Co., Ltd., H1 2016 115
Metastatic Breast Cancer - Pipeline by Genelux Corporation, H1 2016 116
Metastatic Breast Cancer - Pipeline by Genentech, Inc., H1 2016 117
Metastatic Breast Cancer - Pipeline by Genor BioPharma Co., Ltd., H1 2016 118
Metastatic Breast Cancer - Pipeline by Gilead Sciences, Inc., H1 2016 119
Metastatic Breast Cancer - Pipeline by Glycotope GmbH, H1 2016 120
Metastatic Breast Cancer - Pipeline by GTx, Inc., H1 2016 121
Metastatic Breast Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2016 122
Metastatic Breast Cancer - Pipeline by Hetero Drugs Limited, H1 2016 123
Metastatic Breast Cancer - Pipeline by Immune Design Corp., H1 2016 124
Metastatic Breast Cancer - Pipeline by Immunomedics, Inc., H1 2016 125
Metastatic Breast Cancer - Pipeline by Immupharma Plc, H1 2016 126
Metastatic Breast Cancer - Pipeline by Imugene Limited, H1 2016 127
Metastatic Breast Cancer - Pipeline by Incyte Corporation, H1 2016 128
Metastatic Breast Cancer - Pipeline by Intas Pharmaceuticals Ltd., H1 2016 129
Metastatic Breast Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2016 130
Metastatic Breast Cancer - Pipeline by Johnson & Johnson, H1 2016 131
Metastatic Breast Cancer - Pipeline by Kadmon Corporation, LLC, H1 2016 132
Metastatic Breast Cancer - Pipeline by Kancera AB, H1 2016 133
Metastatic Breast Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2016 134
Metastatic Breast Cancer - Pipeline by Laboratoires Pierre Fabre SA, H1 2016 135
Metastatic Breast Cancer - Pipeline by Mabion SA, H1 2016 136
Metastatic Breast Cancer - Pipeline by MacroGenics, Inc., H1 2016 137
Metastatic Breast Cancer - Pipeline by MandalMed, Inc., H1 2016 138
Metastatic Breast Cancer - Pipeline by Meabco A/S, H1 2016 139
Metastatic Breast Cancer - Pipeline by MedImmune, LLC, H1 2016 140
Metastatic Breast Cancer - Pipeline by Medivation, Inc., H1 2016 141
Metastatic Breast Cancer - Pipeline by Merck & Co., Inc., H1 2016 142
Metastatic Breast Cancer - Pipeline by Merck KGaA, H1 2016 143
Metastatic Breast Cancer - Pipeline by Merrimack Pharmaceuticals, Inc., H1 2016 144
Metastatic Breast Cancer - Pipeline by Merus B.V., H1 2016 145
Metastatic Breast Cancer - Pipeline by MetaStat, Inc., H1 2016 146
Metastatic Breast Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2016 147
Metastatic Breast Cancer - Pipeline by Morphotek, Inc., H1 2016 148
Metastatic Breast Cancer - Pipeline by Mycenax Biotech Inc., H1 2016 149
Metastatic Breast Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2016 150
Metastatic Breast Cancer - Pipeline by NantKwest, Inc., H1 2016 151
Metastatic Breast Cancer - Pipeline by Natco Pharma Limited, H1 2016 152
Metastatic Breast Cancer - Pipeline by Nektar Therapeutics, H1 2016 153
Metastatic Breast Cancer - Pipeline by NewLink Genetics Corporation, H1 2016 154
Metastatic Breast Cancer - Pipeline by Nippon Kayaku Co., Ltd., H1 2016 155
Metastatic Breast Cancer - Pipeline by Northwest Biotherapeutics, Inc., H1 2016 156
Metastatic Breast Cancer - Pipeline by Novartis AG, H1 2016 157
Metastatic Breast Cancer - Pipeline by Oasmia Pharmaceutical AB, H1 2016 158
Metastatic Breast Cancer - Pipeline by OBI Pharma, Inc., H1 2016 159
Metastatic Breast Cancer - Pipeline by Oncobiologics, Inc., H1 2016 160
Metastatic Breast Cancer - Pipeline by Oncolytics Biotech Inc., H1 2016 161
Metastatic Breast Cancer - Pipeline by OncoMed Pharmaceuticals, Inc., H1 2016 162
Metastatic Breast Cancer - Pipeline by Oncothyreon Inc., H1 2016 163
Metastatic Breast Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2016 164
Metastatic Breast Cancer - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016 165
Metastatic Breast Cancer - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2016 166
Metastatic Breast Cancer - Pipeline by Pfizer Inc., H1 2016 167
Metastatic Breast Cancer - Pipeline by Pharma Mar, S.A., H1 2016 168
Metastatic Breast Cancer - Pipeline by PIQUR Therapeutics AG, H1 2016 169
Metastatic Breast Cancer - Pipeline by Plexxikon Inc., H1 2016 170
Metastatic Breast Cancer - Pipeline by Polaris Pharmaceuticals, Inc., H1 2016 171
Metastatic Breast Cancer - Pipeline by Polyphor Ltd., H1 2016 172
Metastatic Breast Cancer - Pipeline by Prescient Therapeutics Limited, H1 2016 173
Metastatic Breast Cancer - Pipeline by Prima BioMed Ltd., H1 2016 174
Metastatic Breast Cancer - Pipeline by Puma Biotechnology, Inc., H1 2016 175
Metastatic Breast Cancer - Pipeline by Radius Health, Inc., H1 2016 176
Metastatic Breast Cancer - Pipeline by Samyang Holdings Corporation, H1 2016 177
Metastatic Breast Cancer - Pipeline by Sanofi, H1 2016 178
Metastatic Breast Cancer - Pipeline by Seattle Genetics, Inc., H1 2016 179
Metastatic Breast Cancer - Pipeline by Shanghai Henlius Biotech Co., Ltd., H1 2016 180
Metastatic Breast Cancer - Pipeline by Starpharma Holdings Limited, H1 2016 181
Metastatic Breast Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd., H1 2016 182
Metastatic Breast Cancer - Pipeline by Syndax Pharmaceuticals, Inc., H1 2016 183
Metastatic Breast Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2016 184
Metastatic Breast Cancer - Pipeline by Synthon Holdings BV, H1 2016 185
Metastatic Breast Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2016 186
Metastatic Breast Cancer - Pipeline by TRACON Pharmaceuticals, Inc., H1 2016 187
Metastatic Breast Cancer - Pipeline by Transgene Biotek Limited, H1 2016 188
Metastatic Breast Cancer - Pipeline by Vaxil Bio Therapeutics Ltd., H1 2016 189
Metastatic Breast Cancer - Pipeline by Verastem, Inc., H1 2016 190
Metastatic Breast Cancer - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 191
Metastatic Breast Cancer - Pipeline by VioQuest Pharmaceuticals, Inc., H1 2016 192
Metastatic Breast Cancer - Pipeline by Wilex AG, H1 2016 193
Metastatic Breast Cancer - Pipeline by WntResearch AB, H1 2016 194
Metastatic Breast Cancer - Pipeline by ZIOPHARM Oncology, Inc., H1 2016 195
Metastatic Breast Cancer - Pipeline by Zymeworks Inc., H1 2016 196
Assessment by Monotherapy Products, H1 2016 197
Assessment by Combination Products, H1 2016 198
Number of Products by Stage and Target, H1 2016 200
Number of Products by Stage and Mechanism of Action, H1 2016 213
Number of Products by Stage and Route of Administration, H1 2016 222
Number of Products by Stage and Molecule Type, H1 2016 224
Metastatic Breast Cancer Therapeutics - Recent Pipeline Updates, H1 2016 714
Metastatic Breast Cancer - Dormant Projects, H1 2016 1049
Metastatic Breast Cancer - Dormant Projects (Contd..1), H1 2016 1050
Metastatic Breast Cancer - Dormant Projects (Contd..2), H1 2016 1051
Metastatic Breast Cancer - Dormant Projects (Contd..3), H1 2016 1052
Metastatic Breast Cancer - Dormant Projects (Contd..4), H1 2016 1053
Metastatic Breast Cancer - Dormant Projects (Contd..5), H1 2016 1054
Metastatic Breast Cancer - Dormant Projects (Contd..6), H1 2016 1055
Metastatic Breast Cancer - Dormant Projects (Contd..7), H1 2016 1056
Metastatic Breast Cancer - Dormant Projects (Contd..8), H1 2016 1057
Metastatic Breast Cancer - Dormant Projects (Contd..9), H1 2016 1058
Metastatic Breast Cancer - Dormant Projects (Contd..10), H1 2016 1059
Metastatic Breast Cancer - Dormant Projects (Contd..11), H1 2016 1060
Metastatic Breast Cancer - Dormant Projects (Contd..12), H1 2016 1061
Metastatic Breast Cancer - Dormant Projects (Contd..13), H1 2016 1062
Metastatic Breast Cancer - Discontinued Products, H1 2016 1063
Metastatic Breast Cancer - Discontinued Products (Contd..1), H1 2016 1064
Metastatic Breast Cancer - Discontinued Products (Contd..2), H1 2016 1065
Metastatic Breast Cancer - Discontinued Products (Contd..3), H1 2016 1066
Metastatic Breast Cancer - Discontinued Products (Contd..4), H1 2016 1067

List of Figures
Number of Products under Development for Metastatic Breast Cancer, H1 2016 35
Number of Products under Development for Metastatic Breast Cancer - Comparative Analysis, H1 2016 36
Number of Products under Development by Companies, H1 2016 37
Number of Products under Investigation by Universities/Institutes, H1 2016 48
Comparative Analysis by Late Stage Development, H1 2016 49
Comparative Analysis by Clinical Stage Development, H1 2016 50
Comparative Analysis by Early Stage Products, H1 2016 51
Assessment by Monotherapy Products, H1 2016 197
Assessment by Combination Products, H1 2016 198
Number of Products by Top 10 Targets, H1 2016 199
Number of Products by Stage and Top 10 Targets, H1 2016 199
Number of Products by Top 10 Mechanism of Actions, H1 2016 212
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 212
Number of Products by Top 10 Routes of Administration, H1 2016 221
Number of Products by Stage and Top 10 Routes of Administration, H1 2016 221
Number of Products by Top 10 Molecule Types, H1 2016 223
Number of Products by Stage and Top 10 Molecule Types, H1 2016 223